Prion diseases are a group of fatal and incurable neurodegenerative diseases affecting both humans and animals. The principal mechanism of these diseases involves the misfolding the host-encoded cellular prion protein, PrP C , into the disease-associated isoform, PrP Sc . Familial forms of human prion disease include those associated with the mutations G114V and A117V, which lie in the hydrophobic domain of PrP. Here we have studied the murine homologues (G113V and A116V) of these mutations using cell-based and animal models of prion infection. Under normal circumstances, the mutant forms of PrP C share similar processing, cellular localization, and physicochemical properties with wild-type mouse PrP (MoPrP). However, upon exposure of susceptible cell lines expressing these mutants to infectious prions, very low levels of protease-resistant aggregated PrP Sc are formed. Subsequent mouse bioassay revealed high levels of infectivity present in these cells. Thus, these mutations appear to limit the formation of aggregated PrP Sc , giving rise to the accumulation of a relatively soluble, protease sensitive, prion species that is highly neurotoxic. Given that these mutations lie next to the glycine-rich region of PrP that can abrogate prion infection, these findings provide further support for small, protease-sensitive prion species having a significant role in the progression of prion disease and that the hydrophobic domain is an important determinant of PrP conversion.
T ransmissible spongiform encephalopathies (TSE), also known as prion diseases, are a group of transmissible, fatal neurodegenerative disorders affecting both humans and animals. According to the protein-only hypothesis of prion propagation, these diseases are associated with the conformational conversion of the host-encoded cellular prion protein (PrP C ), into an abnormal, disease-associated isoform (PrP Sc ) (1) . Human PrP C contains a flexible N-terminal region and a structured, globular C-terminal region encompassing residues 125 to 231 (2) . In contrast, residues 90 to 230 of PrP Sc form a structured, protease-resistant core (3) (Fig. 1A) .
Mutations within the human prion protein gene (PRNP) have been associated with inherited disease and act in an autosomal dominant fashion. Such mutations occur throughout PrP, although they are predominantly clustered within the C-terminal globular domain (4) . Mutations within the globular domain are believed either to destabilize PrP C and increase its propensity to misfold or to promote the formation of a toxic intermediate conformer during misfolding (5) (6) (7) . Alterations in the octapeptide repeat region within the unstructured N-terminal domain are believed to alter copper and glycosaminoglycan binding affinities (8, 9) . However, the process by which mutations outside these regions of PrP lead to pathogenesis is unclear, and it has been shown that one common pathogenic mutation outside the globular region, P102L, has no effect on the stability of PrP (6, 10) .
The palindromic region of human PrP spans residues 113 to 120 and consists of an alanine-rich stretch of amino acid residues, AGAAAAGA. This region lies outside the structured domain of PrP and shows high conservation across a wide variety of mammalian species (Fig. 1B) (11, 12) . The palindrome has been shown to be important in the conversion of PrP C to PrP Sc : antibodies directed at this region have differing affinities for PrP C or PrP Sc (13) , deletion of this region prevents conversion of both mutant and coexpressed wild-type (wt) PrP (14, 15) , and peptides corre-sponding to the palindrome interfere with in vitro formation of protease-resistant PrP (16) .
We have previously identified a region of PrP within the hydrophobic domain that contains a series of highly conserved glycine residues (12) . This glycine-rich region (GRR) of PrP is important for the conversion of PrP C to PrP Sc , as alterations in this region prevent the propagation of prion infectivity. Furthermore, a polymorphism in human PrP (G127V) has been identified in individuals in the highlands of Papua New Guinea in regions most affected by the kuru epidemic, suggesting that this alteration to human PrP may have protective properties (17) . Other studies have examined regions overlapping the GRR and their effect on prion infection. Deletion of ␤-strand 1, which encompasses residues 127 to 130, prevents conversion of the altered PrP to PrP Sc and blocks conversion of coexpressed wild-type PrP, though it shows no effect on processing and sorting (18) . The A132V mutation, which lies just outside the GRR, prevents the propagation of the 22L scrapie strain, although this is also seen with other point mutations such as R150H, T189V, and M204I (19) . Doppel, which lacks the flexible N-terminal tail and GRR, cannot convert to a PrP Sc -like conformation at low pH, in direct contrast to wild-type PrP (20) .
Two mutations, G114V and A117V, that are associated with inherited human prion diseases are located within the palindrome sequence of PrP and lie immediately upstream of the GRR. These mutations lead to an early-onset form of Gerstmann-Straüssler-Scheinker syndrome (GSS). The reported ages of onset are in the third to fourth decades of life for disease associated with the G114V mutation and in the second to sixth decades of life for the A117V mutation, both of which are earlier than that associated with the most common GSS-causing mutation, P102L, which is in the third to fifth decades of life (21) (22) (23) (24) (25) . In patients carrying the A117V mutation, PrP Sc is largely sensitive to proteinase K (PK) digestion and soluble (26) , and in G114V-carrying patients, PrP Sc is detected at low levels by immunohistochemistry as fine deposits. The physiochemical properties of abnormal PrP associated with the A117V mutation are shared by a transgenic mouse model of GSS(A117V) (27) . These include the relative abundance of abnormal PrP that is soluble and protease sensitive, as well as the appearance of an ϳ13-kDa PrP fragment at late stages of disease progression, which is consistent with observations for GSS(A117V) (27) . In in vitro studies, peptides matching the hydrophobic region which contain the A117V mutation have altered toxicity and amyloid structures compared to wildtype peptides (28) (29) (30) . Collectively, these observations suggest that these mutations affect the formation of aggregated or neurotoxic PrP.
The human G114V and A117V mutations are present in the unstructured region of PrP, making it difficult to elucidate the effects of these mutations on PrP structure and how they may lead to neurodegeneration. The palindrome is known to be important in the process of PrP C -PrP Sc conversion, and therefore we wished to determine whether these mutations affected the folding of PrP and its ability to propagate prion infectivity. We show that mouse PrP C containing the mouse homologue mutations G113V and A116V shows processing and sorting almost identical to those of wild-type mouse PrP C . Following exposure to prion infection, these mutants propagate a prion species that displays lower levels of protease-resistant PrP (rPrP Sc ) than the wild type yet appears to be more lethal by animal bioassay. The proximity of these mutations which cause prion disease to the GRR, which when disrupted prevents PrP conversion, strongly suggests that this region of PrP is a key modulator of prion propagation. As such, it represents a valuable model for examining neurotoxic isomers of PrP.
MATERIALS AND METHODS
Ethics statement. Mice were observed daily for signs of disease and sacrificed under methoxyflurane anesthesia when persistent signs consistent with prion disease were evident, such as reduced motor activity, hunched posture, hind limb paresis, and ataxia. Mice were handled according to prescribed national guidelines (the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes) as directed by the National Health and Medical Research Council (NHMRC) of Australia. The Animal Ethics Committee of the University of Melbourne (Pathology Panel) approved the animal protocol (reference 0810781.1).
Reagents. Unless specified otherwise, all other reagents were from Sigma-Aldrich (St. Louis, MO, USA). Antibodies used for Western blotting and their working dilutions were as follows: anti-PrP antibody ICSM-18 (1:25,000) was from D-GEN (London, United Kingdom); 03R19 (1:25,000) was produced in-house (31); anti-flotillin-1 (1:3000) was from BD Biosciences (Sydney, NSW, Australia), and anti-mousehorseradish peroxidase (HRP) (1:25,000) and anti-rabbit-HRP (1: 25,000) were from GE Healthcare (Sydney, NSW, Australia). Sequence alignments. Sequences of PrP from various species were retrieved from Swiss-Prot databases and aligned using CLUSTALW (EBI).
Mutagenesis.
The mouse PrP open reading frame was cloned into the pIRESpuro2 vector (Clontech, Palo Alto, CA, USA) as previously described (32) . Oligonucleotide primers (Sigma-Aldrich) (for G113V, 5=-C CTCAAGCATGTGGCAGTGGCTGCGGCAGCT [forward] and 5=-AGC TGCCGCAGCCACTGACACATGCTTGAGG [reverse]; for A116V, 5=-G GGGCTGCGGCAGCTGGGGCAG [forward] and 5=-CTGCCCCAGCT ACCGCAGCCCC [reverse]) were designed to introduce single mutations using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
Maintenance of cultured cell lines. RK-13 cells (33) were maintained in Dulbecco modified Eagle medium (DMEM) (Life Technologies, Melbourne, VIC, Australia) with 10% (vol/vol) fetal calf serum (FCS) (Life Technologies), 1ϫ GlutaMax (Life Technologies), and 100 g/ml penicillin-streptomycin (Pen-Strep) (Life Technologies). pIRES-MoPrP constructs were transfected with Lipofectamine 2000 (Life Technologies) and stable populations maintained in 2 g/ml puromycin (Life Technologies). Cell infections were performed as described previously (32) by incubating cells with 1% (wt/vol) M1000-infected mouse brain homogenate (31, 34) in Opti-MEM containing 10% (vol/vol) FCS, 1ϫ GlutaMax, and 100 g/ml Pen-Strep; cells were incubated for 3 days, washed 4 times with phosphate-buffered saline (PBS) (Life Technologies), and passaged as normal.
Confocal microscopy. Transfected cells were plated in -slides (iBidi, Martinsried, Germany) to reach a final confluence of 40% after 2 days of incubation under standard tissue culture conditions. Cells were fixed with 3.2% (wt/vol) paraformaldehyde and permeabilized in 0.2% (vol/vol) Triton X-100 solution. Cells were blocked with 10% (vol/vol) goat serum (Life Technologies)-2% bovine serum albumin (BSA) (Sigma-Aldrich) in PBS. The primary antibody was ICSM-18 (1:250) in blocking solution, and the secondary antibody was Alexa-488-conjugated anti-mouse (1: 500; Life Technologies), with DAPI (4=,6=-diamidino-2-phenylindole) (1: 1,000; Life Technologies) for nuclear staining. Chamber slides were viewed on a Leica (Solms, Germany) DMIRE2 confocal microscope.
Solubility assay for PrP C expressed in RK13 cells. Cell pellets were mixed with lysis buffer containing cOmplete Ultra protease and incubated for 15 min on ice. Benzonase nuclease (1 l/ml, 10,000 units) (MerckMillipore) was added and samples incubated for 10 min to digest nucleic acids. Total protein concentrations were determined using the bicinchoninic acid (BCA) assay, and cell lysates containing 100 g of total protein was adjusted to a final volume of 1 ml and a concentration of 5% (wt/vol) sodium lauroyl sarcosinate (Sarkosyl; Sigma-Aldrich) in 20 mM Tris, pH 8.0. Samples were incubated on ice for 20 min before being centrifuged (100,000 ϫ g, 1 h, 4°C) in a TLA 100.2 rotor (Beckman Coulter). The supernatant was recovered and the pellet resuspended in an equal volume of 5% (wt/vol) Sarkosyl buffered with 10 mM Tris, pH 8.0. Samples were then methanol precipitated for further analysis by Western immunoblotting.
Isolation of DRMs. Isolation of detergent-rich microdomains (DRMs) was performed using a previously published method (35) . Cells were resuspended in Dulbecco's PBS (DPBS) on ice and lysed by sequential passage through needles; the lysate was rotated in 1% (vol/vol) Triton X-100 at 4°C for 1 h and then mixed with an equal volume of 80% (wt/vol) sucrose. A discontinuous sucrose gradient of 30% (wt/vol) and 5% (wt/ vol) was overlaid in 14-by 89-mm tubes (Beckman Coulter, Fullerton, CA, USA) and centrifuged at 100,000 ϫ g for 18 h in an Optima L-100 XP ultracentrifuge (Beckman Coulter) with an SW41 Ti rotor (Beckman Coulter). One-milliliter fractions were collected from the top down, and proteins were precipitated by addition of 1/5 volume trichloroacetic acid. Pellets were washed in acetone and resuspended in PBS before analysis by Western blotting.
Isolation of exosomes. Exosome isolation from RK13 cells was performed as described previously (32) . Cells were cultured for 3 to 4 days prior to collection of medium. Cellular debris was removed by centrifugation at 3,000 ϫ g for 10 min, the supernatant was filtered (0.2 m), and exosomes were pelleted at 100,000 ϫ g for 1 h at 4°C. Pellets were washed in filtered PBS, repelleted, and then resuspended in a small volume of PBS.
Western blotting. SDS-polyacrylamide gels were transferred to polyvinylidene difluoride (PVDF) membranes, blocked with 5% (wt/vol) skim milk in PBS plus 0.05% Tween 20, and probed with anti-PrP antibody 03R19 or ICSM-18. Blots were visualized with HRP-linked secondary antibody and ECLPlus.
Cell immunoblots. Cells were grown to confluence on plastic coverslips (Thermanox; Nunc-Thermo) and transferred to nitrocellulose membranes for in situ proteolysis with proteinase K (PK) and immunostaining with anti-PrP antibody ICSM-18, as previously described (36) .
Protease treatment of cell lysate. Cells were lysed in lysis buffer (1% [wt/vol] sodium deoxycholate, 0.5% Triton X-100, 150 mM NaCl, 50 mM Tris, pH 7.4) for 15 min on ice. Aliquots (50 l) of postlysis supernatant were taken and mixed with 50 l 100-g/ml PK or 50 l 100-g/ml thermolysin (Sigma). Reaction mixtures were incubated for 1 h at 37°C before reactions were halted with 5 mM phenylmethylsulfonyl fluoride (PMSF). Proteins were then analyzed by Western blotting.
Animal bioassay of prion-infected cell lines. Prion-infected RK13 cells were resuspended, washed in Dulbecco's PBS, and lysed by 5 sequential freeze-thaw cycles. The equivalent of 3 ϫ 10 5 cells was inoculated into the left parietal regions of Tga20 transgenic mice (37, 38) .
Immunohistochemistry. Brains were removed from culled mice and bisected along the sagittal plane. The right hemisphere was fixed in neutral buffered formalin (10% formalin, 29 mM NaH 2 PO 4 · H 2 O, 46 mM Na 2 HPO 4 , pH 7) for 1 month, decontaminated by immersion in 100% formic acid, and immobilized in paraffin blocks by the Histology Facility in the Department of Pathology, University of Melbourne. Sagittal slices were stained with hematoxylin and eosin, anti-glial fibrillary acidic protein (GFAP) antibody, or ICSM-18 antibody, mounted on glass slides, and scanned with a Mirax Scan digital slide scanner (Carl Zeiss AG, Oberkochen, Germany).
Protease treatment of Tga20 brain homogenate. Tga20 left-brain hemispheres were weighed, a volume of PBS equivalent to 9 times the brain mass was added, and the mixture was homogenized by serial needle passage to create a final 10% homogenate. Ten percent homogenates were mixed with 100 g/ml proteinase K and 0.1% (wt/vol) SDS to assist the degradation of PrP C and then incubated at 37°C for 1 h. Digestion was halted with 5 mM PMSF, and proteins were then analyzed by Western blotting.
Velocity gradient separation of PrP species. Velocity gradient separation of PrP species was performed on ice or at 4°C. Cells were resuspended in PBS containing 2ϫ Complete protease inhibitors (Roche), and an equal volume of 2ϫ solubilization buffer (50 mM HEPES [pH 7.4], 300 mM NaCl, 10 mM EDTA,
) was added and incubated on ice for 30 min. Samples were centrifuged at 800 ϫ g for 3 min, the postnuclear supernatant (PNS) was collected, and total protein was measured by BCA assay (Pierce). Five hundred micrograms of total protein was diluted to 250 l with 1ϫ solubilization buffer and 250 l 1ϫ solubilization buffer containing 4% (wt/vol) Sarkosyl (N-lauryl sarcosine; Sigma) was added to afford a final concentration of 2% (wt/vol) and incubated for a further 30 min on ice. The whole volume was loaded on a 10-ml continuous 5 to 25% iodixanol gradient (Optiprep; Sigma), with final concentrations of 25 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1 mM DTT, and 0.5% Sarkosyl. The gradients were centrifuged at 250,000 ϫ g for 1 h in a swinging-bucket SW41 rotor using an Optima L-100 XP ultracentrifuge (Beckman Coulter). Gradients were manually fractionated from the top down into 17 equal fractions of 600 l. Fractions were methanol precipitated for protein analysis or in vitro bioassay using the prion-infected-cell assay (PICA).
PICA. Briefly, 200-l aliquots of velocity gradient fractions were treated with methanol (1:4) and stored overnight at Ϫ20°C to precipitate proteins. This has been previously shown not to affect prion infectivity (39) . The precipitates were resuspended in 100 l Opti-MEM containing 10% (vol/vol) FCS, 1ϫ GlutaMax, and 100 g/ml Pen-Strep and used to inoculate MoRK13 cells (10,000 cells/well in a 96-well microplate [Nunc]) in triplicate (30 l/well). After 16 h, additional medium was added to a final volume of 200 l, and culture was performed as previously described (39) . After 6 passages, cells were lysed and transferred to a methanolactivated 96-well MultiScreen HTS IP enzyme-linked immunosorbent spot (ELISpot) assay plate (Millipore). Proteolysis and immunodetection of rPrP Sc were performed as described previously (39, 40) . PMCA assay. The protein misfolding cyclic amplification (PMCA) assay was performed as described previously (39) with minor modifications. Lysates from M1000-infected RK13 cells were diluted to a final total protein concentration of 0.5 mg/ml in PMCA conversion buffer (39) , and 10 l of this was used to seed 90 l PMCA normal brain homogenate substrate prior to one round of PMCA. Alternatively, brain homogenates from the animal bioassay, at a stock concentration of 10% (wt/vol) in PBS, were diluted in PMCA conversion buffer (39) , and 10 l of this was used to seed 90 l PMCA normal brain homogenate substrate prior to one round of PMCA.
RESULTS
The G113V and A116V mutations do not alter the biochemical and cellular properties of PrP C . The murine homologues (G113V and A116V) of the human-pathogenic mutations G114V and A117V were created by site-directed mutagenesis and the resulting constructs transfected into the RK13 rabbit kidney epithelial cell line, which is capable of continuously propagating prion infection once stably transfected with exogenous prion genes (33) . Stable expression of MoPrP mutations was established in RK13 cells by selection with puromycin and the characteristics of PrP characterized.
The expression of PrP C was analyzed by Western immunoblotting ( Fig. 2A) , which demonstrated that, like MoPrP, the G113V and A116V mutant PrP C has similar, heterogenous glycoforms, indicating that these two mutations were not affecting the glycosylation of PrP C . The heterogeneous glycosylation of PrP expressed by the RK13 cell line has been described previously (41) . As previously reported, PrP is not detected in wild-type (wt) RK13 cells (33) . To determine if the pathogenic mutations were leading to gross alterations in protein localization, cell lines were examined using immunofluorescence microscopy. Imaging of nonpermeabilized (data not shown) and permeabilized cells revealed that both wild-type and mutant mouse PrP C were localized predominantly to the extracellular face of the plasma membrane (Fig. 2B) , which is consistent with previous reports of MoPrP (42) . Some intracellular staining was also observed at a juxtanuclear position which we determined to be associated with the Golgi apparatus (data not shown). A pelleting assay employing ultracentrifugation of cell lysates demonstrated that expression of the mutant PrP C in RK13 cells did not produce any pelletable aggregates (Fig. 2C) .
In humans, the G114V and A117V mutations are associated with a form of inherited prion disease and the accumulation of abnormal PrP. Velocity gradient sedimentation analysis using a 5 to 25% iodixanol (Optiprep) gradient was used to determine if these mutations were facilitating the misfolding of PrP into an aggregated form in the transfected RK13 cells. This technique has been described previously to analyze the aggregation state of PrP associated with different prion strains from the brains of diseased animals (43) . Following velocity gradient sedimentation of MoPrP, G113V, and A116V RK13 cell lysates, Western immunoblotting was used to detect PrP in the gradient fractions ( Fig. 2D and 3 ). This revealed that in the MoPrP, G113V, and A116V gradients, PrP appeared in fractions 1 to 6 (although a small proportion of PrP C does appear in the bottom fraction 17 in the G113V and A116V gradients). This indicates that the PrP C in these samples is predominantly soluble and not aggregated; that is, the mutations do not cause any gross alterations to the quaternary structure of PrP C . Velocity gradient sedimentation was also performed on mouse brain homogenate and fractions screened for PrP. Again, minimal difference in the sedimentation profiles between the MoPrP, G113V PrP, A116V PrP, and brain PrP C were observed, indicating that PrP C expressed in the RK13 cell line has characteristics typical of in vivo-derived PrP C .
To further characterize these cell lines, we analyzed the sorting of mutant PrP into compartments known to be important in prion infection. Exosomes have been shown to carry significant prion infectivity between cells and may play a role in prion spread throughout the body (39, 44, 45) . We determined that like MoPrP, G113V and A116V PrP C was correctly sorted into exosomes (Fig.  4A ). PrP C is a glycosylphosphatidylinositol (GPI)-anchored protein which normally resides in lipid rafts; this localization has been shown to be important for uptake of infectious prions (46, 47) . Purification of lipid rafts was performed and indicated that MoPrP, as well as the G113V and A116V mutants, was correctly localized to lipid rafts. While all partitioned into the raft fractions, some A116V and G113V PrP was found in the30 to 40% boundary fractions (Fig. 4B ). PrP C undergoes proteolytic processing yield- ing fragments associated with normal processing (C1, residues 110 to 230) and disease (C2, residues 90/91 to 230) (48, 49) . Cell lysates were deglycosylated with peptide-N-glycosidase F (PNGase F) to determine the formation of these proteolytic fragments, revealing three bands representing full-length PrP and the C2 and C1 fragments (Fig. 4C) . Quantification of the proportion of PrP in each of these forms demonstrates that the A116V mutations lead to a minor but significant increase in the C2 fragment (Fig.  4D ).This is consistent with previous reports of transgenic mice expressing the A116V mutation, which have been shown to have altered C1 and C2 levels (27) . RK13 cells expressing G113V or A116V produce lower levels of protease-resistant PrP than MoPrP following exposure to the M1000 prion strain. As the mutations being analyzed are associated with inherited prion disease, we wished to determine if they affected the ability of transfected RK13 cells to propagate prions. Cells were exposed to the M1000 prion strain (50), a mouseadapted human strain originally isolated from a Japanese patient with Gerstmann-Straüssler-Scheinker (GSS) syndrome linked to a P102L mutation in PRNP (51) . The progress of prion infection was followed by the increase in the levels of rPrP Sc in cultures over multiple passages as determined by cell immunoblotting (36) . As previously shown (41) prion-exposed RK13 cells expressing MoPrP develop rPrP Sc ( Fig. 2A) . Following prion infection of cells expressing the G113V and A116V mutant forms of PrP, a reduced amount of rPrP Sc was detected (Fig. 5A , B, and C). Continued passage of infected cells leads to an increase in rPrP Sc levels in MoPrP-and G113V-infected RK13 cells, although rPrP Sc levels remain low in A116V-RK13 cells (data not shown). In contrast, long-term passage of control (noninfected) cells did not result in the spontaneous formation of PrP Sc , as has been reported in other studies (52) . No differences in cytotoxicity and cell growth rates were observed in RK13 cells expressing MoPrP or mutants either prior to or following exposure to prions, indicating that the observed reduction in rPrP Sc levels is not due to cell death (data not shown).
Protease digestion with proteinase K (PK) was used to determine the biochemical properties of mutant PrP Sc . PK digestion at a range of concentrations demonstrated that A116V rPrP Sc is sensitive to much lower concentrations of PK than MoPrP and G113V rPrP Sc (Fig. 5 B) . Quantitation of Western blots (including that in Fig. 5B ) of products treated with PK at a concentration of 50 g/ml revealed that both G113V and A116V have a statistically significant decrease in the amount of rPrP Sc compared to MoPrP (Fig. 5C ). Thermolysin, a protease that has previously been used to distinguish prion strains and detect PK-sensitive PrP Sc (sPrP Sc ) (53), was used to digest lysate samples (Fig. 5D ). MoPrP and G113V PrP Sc showed similar levels of resistance to both PK and thermolysin. However, A116V PrP Sc is more resistant to thermolysin than PK (Fig. 5D) . This difference in protease resistance suggests that the A116V mutation is forming an altered conformation of PrP Sc .
Differences in PrP
Sc conformations could also lead to variations in the aggregation state of PrP Sc . Therefore, velocity gradient sedimentation was used to assess the forms of PrP aggregates produced in the RK13 cells expressing MoPrP, G113V, and A116V. For comparative purposes, the PrP aggregates in the brain homogenates from M1000-infected mice were also fractionated by velocity gradient sedimentation. Following fractionation and Western blotting of the M1000 MoPrP-brain homogenates, PrP was detected in fractions 1 to 14 ( Fig. 6A and 3B ). This broad distribution suggests that a diverse array of different-sized PrP aggregates were present in the diseased mouse brains. The RK13 cell-derived M1000 MoPrP sedimentation profile shared similar features with the M1000 MoPrP-brain gradient: PrP was detected in fractions 1 to 13 but was most abundant in the denser fractions (4 to 11). This is indicative of larger PrP aggregates being present in the M1000 MoPrP RK13 cells ( Fig. 6A and 3B ). M1000 G113V shared a similar distribution of PrP (although at a lower abundance than M1000 MoPrP) restricted to the central regions (fractions 8 to 10) of the gradient, indicating that PrP aggregates do form in RK13 cells expressing this mutation (Fig. 6A and 3B ). However, G113V also showed similarities to the A116V PrP sedimentation profiles, where a large abundance of PrP was found localizing to the less dense fractions (the upper region of the gradient).This is indicative of much smaller aggregates, i.e., oligomers and/or monomers ( Fig. 6A and 3B ). In particular, PrP associated with A116V was restricted to fractions 1 to 5, with none detected in fractions outside this area. These observations further indicate that PrP Sc associated with the M1000 G113V and A116V mutations is different Sc is detected at lower levels in G113V RK13 cells and is barely detectable in A116V RK13 cells. Ponceau stain was used to detect total protein demonstrating similar levels of protein between each group before treatment with proteinase K. No rPrP Sc 
is detected in control cells (mock infected). (B)
Lysates of infected cells were treated with increasing amounts of proteinase K. MoPrP and G113V PrP displayed partial resistance to even the highest PK concentration tested (50 g/ml), whereas A116V PrP showed partial resistance to only the lowest concentration tested (10 g/ml). (C) Quantitation of Western immunoblots (n ϭ 3, including panel B, 50-g/ml PK lane) showing levels of protease-resistant PrP normalized to total PrP. M1000-infected G113V and A116V display significantly lower levels of rPrP Sc than M1000 MoPrP. One-way ANOVA with Tukey's multiple-comparison test was used to compare mutants to MoPrP; ***, P Յ 0.001; error ϭ SEM. (D) Lysates of infected cells were digested with the proteases thermolysin and proteinase K at 100 g/ml for 1 h. MoPrP and G113V PrP showed similar resistance to digestion by both proteases. In contrast, A116V PrP was more highly resistant to thermolysin than to PK. from wild-type MoPrP, having a greater proportion of small, slow-sedimenting PrP species, as opposed to the larger aggregates found associated with M1000 MoPrP-brain and M1000 MoPrP.
We then investigated whether these slow-sedimenting PrP species were associated with prion infectivity. The contents of every third fraction was screened for infectivity using the prion-infected-cell assay (PICA) (39) . The PICA is a high-through-put in vitro bioassay similar to the standard scrapie cell assay (SSCA) (40) that utilizes the readily infectible RK13 cell line expressing MoPrP (MoRK13) as the recipient cell line. Following exposure to prions and subsequent passage, these MoRK13 cells propagate their own rPrP Sc , which is indicative of infection. This rPrP Sc can be detected by protease digestion and immunodetection using an enzymelinked immunosorbent assay (ELISA)-based method in a fashion similar to that for the SSCA. The presence of rPrP Sc was detected at the highest level in the recipient MoRK13 cells following exposure to the central fractions (fractions 6 to 12) of the M1000 MoPrP gradient (Fig. 6A and B) . The highest level of infectivity was detected in fraction 6, which correlates with the presence of high levels of PrP found in the fractions (Fig. 6A) . The presence of infectivity in fractions 6 to 12 indicates that it is associated with PrP Sc aggregates, as opposed to the smaller species that are ex- were detected in cells exposed to fractions 9 and 12 of the G113V gradient, and very low levels were detected in cells exposed to fractions 6 and 9 of the A116V gradients. PrP was detected in the PICA with anti-PrP antibody ICSM-18 (n ϭ 3; error ϭ SEM; % RFU rPrP Sc inoculated/mock ϭ rPrP Sc immunodetection in relative fluorescence units [QuantaBlue fluorescent HRP substrate] of MoRK13 PICA cells exposed to infectious inoculum normalized to those exposed to control [mock-infected] MoRK13 PICA cells). (C) MoPrP-RK13 cells were exposed to lysates from M1000-infected (i) RK13 cells expressing MoPrP or mutants. The presence of rPrP Sc in MoPrP RK13 cells was detected by cell blot assay at passage 6 postinfection using anti-PrP antibody ICSM-18. rPrP Sc was detected in MoPrP RK13 cells exposed to M1000 MoPrP lysates, and to a lesser degree in those exposed to M1000 G113V lysates, but not M1000 A116V lysates. (D) Noninfected (N) and infected (I) Mo-, G113V-, or A116V-RK13 cell lysate (10 l) was used to seed mouse brain homogenate (90 l; 10%, wt/vol) and subjected to one 24-h round of PMCA followed by digestion with PK (50 g/ml) and Western blotting using anti-PrP antibody 03R19. rPrP Sc was detected only in reaction mixtures seeded with infected MoPrP-RK13 and control 0.1% (wt/vol) M1000 (marked by a black box). *, bands pertain to incomplete digestion of PrP C . Results are representative of two repeats. (E) The PMCA products from panel D were used to seed fresh mouse brain homogenate PMCA substrate, and a second 24-h round of PMCA was performed. rPrP Sc was readily detected in all seeded reaction mixtures by Western immunoblotting with anti-PrP antibody 03R19. The black star marks a nonspecific PK band. Results are representative of two repeats.
pected to be found in the upper fractions. This finding is consistent with a previous study that found that rPrP Sc and the majority of infectivity peaked at the center of a 10 to 25% Optiprep gradient used to separate infected mouse brain PrP (43) . Similar to the case for the MoPrP gradient, infectivity was detected in the central-tolower region in the G113V gradient, albeit at only half the level for MoPrP (Fig. 6B, fractions 9 and 12) . Interestingly, only fraction 9 correlated with the presence of high levels of PrP. That is, PrP was barely detectable in fraction 12, despite the presence of high levels of rPrP Sc formation in the recipient cells (Fig. 6B) . In contrast to the case for MoPrP and G113V, infectivity (in terms of inducing the formation of rPrP Sc in the recipient cells) was barely detectable in any fraction of the A116V gradient. This could be due to a seeding-incompetent species being produced in the A116V mutant cells, or, as only low levels of rPrP Sc are produced in cells expressing the A116V mutant, this phenotype may be being mirrored in the recipient PICA cells. To ensure that this result was not specific to the PICA, the traditional cell blot assay was used and MoPrP cells were exposed to whole M1000 MoPrP, G113V, or A116V lysates. Consistent with the PICA results in Fig. 6B , the M1000 G113V lysate-exposed MoRK13 cells produced low levels of rPrP Sc , and rPrP Sc was undetectable in cells exposed to M1000 A116V lysates (Fig. 6C) .
To explore whether this phenomenon was due to a cellular process of the RK13 cells or whether it was specifically due to changes in the misfolding PrP such as a failure of the mutants to seed conversion, lysates of M1000 RK13 cells expressing MoPrP or the mutants were tested for the ability to seed the in vitro conversion of PrP C (provided in the normal mouse brain homogenate used as a substrate) using the protein misfolding cyclic amplification (PMCA) assay (54, 55) . Following one 24-hour round of PMCA, newly formed mouse brain rPrP Sc was readily detected in the reaction mixtures seeded with M1000 MoPrP lysates, partially in those seeded with M1000 G113V, and not at all in M1000 A116V-seeded reaction mixtures (Fig. 6D) . This could be due to the inability of the mutants to seed conversion or to the inducement of the brain PrP C to a protease-sensitive conformation, or possibly PMCA has a preference for amplifying rPrP Sc , which is inherently low in the mutant cell lysates. A second 24-hour PMCA round was performed in which the products of the first PMCA round were used to seed fresh mouse brain homogenate substrate and subjected to PMCA. Following this second round, newly formed rPrP Sc was detected in reaction mixtures seeded with the round one products originally seeded with the mutants (Fig. 6E) . This provides evidence confirming that the original mutant-expressing RK13 cell lines were indeed infected following exposure to M1000. Importantly, this finding suggests that PMCA preferentially converts rPrP Sc , and thus replication is delayed in reaction mixtures seeded with the mutant lysates, as they have small amounts of rPrP Sc . Alternatively, if the M1000-infected mutant-expressing RK13 cells are producing a new PrP Sc conformation, this may be unstable on the MoPrP background provided in the normal mouse brain homogenate used as the substrate in PMCA.
Prion-infected RK13 G113V and A116V lysates lead to earlier death than infected MoPrP in mouse bioassay. The findings of this study suggest the M1000 RK13 cells expressing the familial mutations G113V and A116V were propagating an altered conformer of PrP Sc . However, given that both the PICA and PMCA assay ultimately rely on the detection of rPrP Sc (which was inherently low in these M1000 mutant cells), it was difficult to conclusively determine if prions were in fact being propagated. Therefore, the infected-cell lysates were tested by mouse bioassay for the presence of prion infection. Cells were lysed via passage through small-gauge needles and the resulting homogenate inoculated into the left parietal regions of Tga20 mice (37) . Tga20 mice, which overexpress PrP approximately 4-fold relative to wild-type mice, act as a sensitive and physiologically relevant detector of prion infectivity (56) . As expected, mice inoculated with M1000 MoPrP-RK13 lysate developed symptoms of prion disease, which progressed to terminal illness after a mean of 126 days Ϯ 6 days (standard error of the mean [SEM]) ( Table 1 ). In contrast, mice inoculated with M1000 wild-type RK13 cells did not develop any symptoms of prion disease, remaining healthy until the end of the experiment. Mice inoculated with M1000 G113V lysate were observed to succumb to disease after a mean of 113 days (Ϯ2 days [SEM]). While this was earlier than observed with M1000 MoPrP-RK13 lysate-inoculated animals, the difference was not statistically significant (P ϭ 0.073). Inoculations with M1000 A116V lysate led to terminal illness at a mean of 101 days (Ϯ3 days [SEM] ). This was significantly earlier than that with M1000 MoPrP-RK13 lysate (P Ͻ 0.01). Thus, despite the M1000 A116V-RK13 cells displaying reduced levels of rPrP Sc , a significantly shorter time to death was observed in comparison to that with M1000 MoPrP-RK13 cells, suggesting the presence of a more toxic and protease sensitive form of PrP Sc . Brains of culled animals were fixed and stained for neuropathological analysis. As shown previously (12), Tga20 mice inoculated with M1000 MoPrP-RK13 lysate developed spongiform change, astrocytic proliferation, and deposition of PrP-immunoreactive plaques (Fig. 7) . No pathological change was observed in the brains of healthy mice inoculated with wild-type RK13 lysate. Spongiform change, astrocytosis, and PrP deposition were observed in mice inoculated with G113V-and A116V-RK13 cell lysates, indicating that these animals had indeed succumbed to prion disease.
We next examined the attributes of PrP Sc derived from the brains of inoculated animals. Protease treatment of brain homogenates was performed, followed by Western immunoblotting, and revealed the typical three-band pattern of di-, mono-, and unglycosylated PrP (Fig. 8A) (57) . Quantification of rPrP Sc levels following digestion was performed and demonstrated a significantly decreased level of rPrP Sc in the brains of mice inoculated with A116V-RK13 lysate (P Ͻ 0.01) (Fig. 8B) , which is in keeping with the decreased PrP Sc seen in the original inoculum (Fig. 5A ). More detailed quantification was performed to determine the relative proportions of di-, mono-, and unglycosylated PrP Sc ; these proportions are used in prion protein glycotyping as a method to distinguish between multiple prion strains (58) . The relative proportions of rPrP Sc in brains from MoPrP-and G113V-inoculated animals appeared to be statistically indistinguishable (Fig. 8C) . In contrast, A116V-inoculated animals showed a highly significant increase in the monoglycosylated band (P Ͻ 0.001) with a concurrent decrease in diglycosylated PrP Sc (P Ͻ 0.05), indicative of an altered prion strain.
Finally, the brain homogenates were used to seed PMCA reaction mixtures to determine if they were capable of converting MoPrP C into rPrP Sc in vitro, despite the brains of mice inoculated with M1000 A116V displaying lower levels of rPrP Sc . Brain homogenates of 3 mice used in each of the groups were used to seed mouse brain PMCA conversion substrate at a final seed concentration of 0.1% (wt/vol). Following one 24-h round of PMCA, the presence of rPrP Sc in the resulting reaction mixtures was detected using Western immunoblotting (Fig. 8D ). All mouse brains tested with PMCA were capable of seeding conversion of PrP C to rPrP Sc in vitro. Quantification of the rPrP Sc levels in the PMCA reaction mixtures and normalization to their respective non-PMCA controls revealed mean rPrP
Sc levels approximately 300% above those in the respective non-PMCA controls (data not shown). Furthermore, no significant difference was detected between the mean rPrP Sc levels in reaction mixtures seeded with M1000 MoPrP-, G113V-, or A116V inoculated brain homogenates (data not shown). Therefore, unlike the first-round PMCA reaction mixtures seeded with the infected-cell lysates (Fig. 6D) , the brain homogenates appear to be capable of seeding the formation of rPrP Sc in vitro despite displaying slightly lower levels of rPrP Sc .
DISCUSSION
There are now more than 30 mutations in the human prion gene (PRNP) that are linked to familial prion diseases (59) . The resultant diseases caused by these mutations differ in terms clinical and pathological features, as well as in the biochemical characteristics of the PrP associated with these diseases. In this study, we have created the murine homologues of the human G114V and A117V pathogenic prion protein mutations and characterized these mutant proteins in a cell culture model. Although some alterations in processing and cleavage were observed, the presence of the G113V or A116V mutation did not alter the localization or expression of PrP. Furthermore, similar to MoPrP C , PrP C associated with G113V and A116V was shown here to be detergent soluble (in agreement with a previous study [60] ), and separation of PrP by velocity gradient sedimentation revealed no gross differences compared to MoPrP.
In this study, we exposed the MoPrP-, G113V-, and A116V-RK13 cells to the M1000 prion strain. While this strain is derived from a GSS case (with a P102L mutation) (51), it was not a case associated with the G113V or A116V mutation. Therefore, it is possible that some observations made in this study were artifacts of the M1000 strain used here. Future studies may look to test other prion strains to address this possibility. That being said, following exposure to M1000, the G113V-PrP and (more so) A116V-PrP displayed differing properties compared to MoPrP. The A116V-RK13 cells produce a considerably lower level of protease-resistant PrP Sc than MoPrP or G113V-RK13 cells. Unlike M1000 MoPrP, large proportions of PrP associated with M1000 G113V (ϳ57%) and A116V (ϳ88%) were found in the upper regions of the 10 to 25% Optiprep gradient. Given that the wholecell lysates were shown to be infectious in mice, it is likely that this upper gradient region also contains the majority of infectivity. Therefore, the PrP Sc produced in the M1000 G113V-and A116V-RK13 cells is likely to consist of small, protease-sensitive (sPrP Sc ) oligomers or aggregates. This is consistent with other studies which have found that sPrP Sc migrates slowly in density or velocity sedimentation gradients, which is indicative of small, low-density oligomers or aggregates (43, 61) .
It was also found that A116V-PrP Sc was retarded in seeding conversion of brain PrP C to rPrP Sc after one round of PMCA; however, after two rounds, rPrP Sc was detected. This suggests that PMCA preferentially converts rPrP Sc or that a new sPrP Sc species is converting the substrate MoPrP C into a protease-sensitive conformation that precludes detection by standard PK digestion and Western blotting for rPrP Sc . The latter suggestion is consistent with the observation that rPrP Sc was not detected in MoPrP cells that were exposed to the M1000 A116V-PrP. In comparison to PrP in the M1000-infected brain homogenate and MoPrP-and G113V-PrP, the biochemical properties of A116V-PrP from infected cells appear to be more closely related to PrP C than to PrP Sc . This suggests that the A116V-PrP Sc is unable to infect MoPrPexpressing RK13 cells or, alternatively, that a protease-sensitive conformer is being produced.
When tested using animal bioassay, the lysates from M1000 A116V-PrP cells resulted in the inoculated mice developing terminal prion disease at significantly earlier time points than those inoculated with M1000 MoPrP or G113V lysates. The formation of brain-derived PrP Sc within the M1000 A116V-inoculated mice was also found to have lower protease resistance and altered gly-
FIG 7
Brains were extracted, fixed, and analyzed for typical markers of prion pathology. Hematoxylin and eosin staining demonstrates the presence of spongiform change in mice inoculated with cell extracts from M1000-infected RK13 cells expressing MoPrP, G113V, and A116V transgenes (arrows) but not in wt RK13 controls. GFAP immunohistochemistry shows astrocytosis in mice inoculated with MoPrP, G113V, and A116V but not wt RK13 cells (arrows). PrP immunohistochemistry with the anti-PrP antibody ICSM-18 demonstrates the formation of plaques in MoPrP-, G113V-, and A116V-inoculated mice but not in wt RK13-inoculated animals (arrows). Images were taken from the thalamus at a magnification of ϫ20.
coform ratios. This suggests that the A116V mutant is allowing propagation of a protease-sensitive, highly neurotoxic prion conformation, leading to a significantly reduced incubation period. Previous work has shown that patient-derived A117V-PrP Sc , while associated with disease in the patient, has limited infectivity when passaged into mice (62) . The infectivity of the mutant cell lysates detected by mouse bioassay in our study is likely due to the creation of the mutation on a mouse PrP background, thus avoiding the human-to-mouse transmission barrier. A transgenic A116V animal model produces abnormal PrP with physicochemical properties similar to those seen in the A116V-RK13 cell model described here, in addition to undergoing the neuropathological changes seen in humans (27) .
The disconnect between protease-resistant PrP and pathogenic PrP has been previously demonstrated in animal models; inoculated mice can develop amyloid deposits but not clinical symptoms (63) or acquire high infectious titers in the absence of protease-resistant material (64) (65) (66) (67) . The abnormal PrP species associated with the human prion diseases involving these mutations has been shown to be weakly protease resistant compared to those in other human prion diseases such as Creutzfeldt-Jakob disease (CJD) (21, 22, 24, 26, (68) (69) (70) . Similarly, A116V PrP Sc from transgenic mice shows low protease resistance (26, 27) . Recent studies indicate that small sPrP Sc oligomers are more infectious and able to replicate faster than larger fibrillar-like rPrP Sc species (71, 72) . The smaller size has been associated with faster neuroinvasion (71), lower thermal and chaotrope stability (71, 72) , and higher in vitro conversion rates (72) . The smaller size may provide more nucleation points for the binding of PrP C substrate with sPrP Sc , facilitating a higher concentration of conversion activity. Furthermore, it is possible that the shortened incubation periods observed in the animal bioassay could result from increased rates of axonal transport, trafficking across the synapse, or a more rapid targeting of susceptible brain regions involved in the pathogenic process.
While the results presented here support the possibility that the primary neurotoxic species in A117V-related GSS could be a smaller, nonamyloid species, more detailed characterization of the structure of the neurotoxic seed is required. There is a growing body of evidence for other neurodegenerative diseases that small, soluble oligomeric species are likely to be the neurotoxic moiety responsible for neurodegeneration (73) (74) (75) (76) (77) (78) (79) (80) . In Alzheimer's disease, studies suggest that the primary source of neurotoxicity resides in small peptide oligomers rather than the larger amyloid deposits commonly associated with the disease (81, 82) . Similarly, ␣-synuclein oligomer-associated toxicity has been reported in Parkinson's disease (83) . Small oligomers of PrP have been reported to be toxic in cultured cells, primary mouse neurons, and ) as a percentage of total PrP; the graph shows mean and SEM. Significantly less rPrP Sc was seen in A116V-inoculated animals (**, P Ͻ 0.01) but not for G113V compared to MoPrP (n ϭ 3 animals for each) (1-way ANOVA). (C) Quantification of glycoform ratios following protease digestion; the graph represents the mean percentage in each form Ϯ SEM (n ϭ 3). MoPrP and G113V have statistically indistinguishable glycoform ratios; A116V showed a statistically significant increase in monoglycosylated (***, P Յ 0.001) and a decrease in diglycosylated (*, P Յ 0.05) forms. (D) PMCA was used to test the brain homogenates for the ability to seed conversion of PrP C . PMCA brain homogenate substrate (10%, wt/vol) was seeded with brain homogenates (0.1%, wt/vol [final concentration]) of mice used in animal bioassay that had been inoculated with lysates of M1000-infected MoPrP-, G113V-, or A116V-RK13 cells and subjected to one 24-h round of PMCA (ϩ); Ϫ indicates samples which did not undergo PMCA. The presence of rPrP Sc was detected in PMCA reaction products by digestion with PK (50 g/ml) and Western immunoblotting using anti-PrP antibody 03R19. Quantitation indicated no significant difference in rPrP Sc levels was observed between different groups.
live animals (79, 84) . It is therefore possible that the increased neurotoxicity and decreased protease resistance of the A116V-PrP Sc are due to increased levels of smaller oligomeric species. Amino acids within the hydrophobic region have been shown to affect the prion oligomerization pathway; a valine residue at codon 129 leads to reduced oligomer formation (85, 86) , while deletion of PrP114-122 in aggregation-prone PrP mutants such as D177N-MoPrP leads to formation of smaller, more soluble aggregates (87) . Solvent exposure of the hydrophobic domain, which contains both G113V and A116V, has been shown to be critical for the neurotoxicity of PrP oligomers (79) . As the A116V mutation has been previously shown to increase hydrophobic interactions with lipids (88) , this may suggest that the increased neurotoxicity associated with A116V-PrP Sc is related to altered oligomer conformation associated with solvent exposure of the hydrophobic region.
In summary, prion infection of cellular G113V and, in particular, A116V PrP mutants appears to lead to the formation of an altered prion strain characterized by decreased protease resistance but a higher degree of toxicity. We believe that this provides an invaluable opportunity to determine the composition of the asyet-unidentified toxic species of prion disease. Given that alterations in the adjacent GRR region prevent the formation of toxic and/or infectious PrP species (Fig. 1) (12) , we propose a two-step mechanism in the formation of PrP Sc . Here, GRR mutants prevent the formation of a toxic intermediate species of PrP, whereas the G113V and A116V mutants allow the generation of this species but prevent rPrP Sc formation. Such a model and the use of mutants presented here provide a system suitable for the identification of pathogenic PrP isoforms in addition to highlighting a highly conserved domain of PrP that may have therapeutic potential.
